title: Human papillomavirus capsids preferentially bind and infect tumor cells.
abstract: We previously determined that human papillomavirus (HPV) virus-like particles (VLPs) and pseudovirions (PsV) did not, respectively, bind to or infect intact epithelium of the cervicovaginal tract. However, they strongly bound heparan sulfate proteoglycans (HSPG) on the basement membrane of disrupted epithelium and infected the keratinocytes that subsequently entered the disrupted site. We here report that HPV capsids (VLP and PsV) have the same restricted tropism for a wide variety of disrupted epithelial and mesothelial tissues, whereas intact tissues remain resistant to binding. However, the HPV capsids directly bind and infect most tumor-derived cell lines in vitro and have analogous tumor-specific properties in vivo, after local or intravenous injection, using orthotopic models for human ovarian and lung cancer, respectively. The pseudovirions also specifically infected implanted primary human ovarian tumors. Heparin and ι-carrageenan blocked binding and infection of all tumor lines tested, implying that tumor cell binding is HSPG-dependent. A survey using a panel of modified heparins indicates that N-sulfation and, to a lesser degree, O-6 sulfation of the surface HSPG on the tumors are important for HPV binding. Therefore, it appears that tumor cells consistently evolve HSPG modification patterns that mimic the pattern normally found on the basement membrane but not on the apical surfaces of normal epithelial or mesothelial cells. Consequently, appropriately modified HPV VLPs and/or PsV could be useful reagents to detect and potentially treat a remarkably broad spectrum of cancers.
authors: Aura Biosciences, Cambridge, MA.
authors: Rhonda C
authors: RC
authors: Kines
authors: Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
authors: Rebecca J
authors: RJ
authors: Cerio
authors: Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
authors: Jeffrey N
authors: JN
authors: Roberts
authors: Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
authors: Cynthia D
authors: CD
authors: Thompson
authors: Aura Biosciences, Cambridge, MA.
authors: Elisabet
authors: E
authors: de Los Pinos
authors: Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
authors: Douglas R
authors: DR
authors: Lowy
authors: Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
authors: John T
authors: JT
authors: Schiller
mesh_terms: D000818:Animals; D002213:Capsid / Q000378:metabolism*; D045744:Cell Line, Tumor; D002469:Cell Separation; D005260:Female; D019812:Heparan Sulfate Proteoglycans / Q000378:metabolism; D052162:Human papillomavirus 16 / Q000378:metabolism*; D006801:Humans; D051379:Mice; D009369:Neoplasms / Q000821:virology*; D030361:Papillomavirus Infections / Q000821:virology*
chemical_list: D019812:Heparan Sulfate Proteoglycans
keywords: heparan sulfate proteoglycans; human papillomavirus; tumor tropism